Steroids in heart surgery: a clinical double-blind and randomized study

Area of Science:

• Cardiology
• Pharmacology
• Critical Care Medicine

Background:

• Cardiopulmonary bypass is a complex procedure associated with significant patient morbidity and mortality.
• The use of corticosteroids, such as methylprednisolone, during cardiac surgery is controversial.
• Previous research has yielded conflicting results regarding the efficacy and safety of steroid administration in this context.

Purpose of the Study:

• To investigate the impact of perioperative methylprednisolone administration on hemodynamic stability, biochemical markers, and survival rates in patients undergoing cardiopulmonary bypass.
• To evaluate the potential benefits and risks associated with using steroids in cardiac surgery.

Main Methods:

• A double-blind, randomized, placebo-controlled trial was conducted with 95 patients undergoing cardiopulmonary bypass.
• The treatment group (47 patients) received repeated intravenous doses of methylprednisolone (30 mg/kg every six hours).
• The control group (48 patients) received an identical placebo regimen.

Main Results:

• No statistically significant differences (P < 0.1) were observed in hemodynamic parameters or biochemical markers between the methylprednisolone and placebo groups.
• A notable improvement in survival rates was observed in the group treated with methylprednisolone.
• The mechanism behind the observed survival benefit remains unclear, as no other biochemical improvements were detected.

Conclusions:

• While methylprednisolone did not significantly alter hemodynamic or biochemical profiles in this study, an improvement in survival was noted.
• Further comprehensive hemodynamic and biochemical analyses are required to elucidate the subtle mechanisms underlying the potential benefits of steroid use in cardiac surgery.
• The findings suggest a potential role for steroids in improving outcomes, warranting additional investigation into their precise effects.